The federal government’s blueprint for fighting Alzheimer’s disease is getting its biggest rewrite in years, and the new version is built around one idea: stopping dementia before it starts.
Health and Human Services Secretary Robert F. Kennedy Jr. announced the 2026 Update to the National Plan to Address Alzheimer’s Disease and Related Dementias on Thursday at Broward Health Medical Center in Fort Lauderdale. He was joined by Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, Acting FDA Commissioner Kyle Diamantas and U.S. Sen. Rick Scott of Florida, who chairs the Senate Special Committee on Aging.
“Under President Trump, HHS is shifting the national strategy toward prevention, earlier detection, and faster development of better diagnostics and treatments,” Kennedy said in the department’s announcement.
At the event, he made it personal. “Several members of my family have faced Alzheimer’s, including my mother, who passed away last year,” Kennedy said, according to the South Florida Sun Sentinel.
What changes in the national Alzheimer’s plan?
The plan, required under the National Alzheimer’s Project Act of 2011, has guided federal dementia policy for more than a decade. The 2026 update throws out its six long-standing goals and replaces them with four that follow brain health across a person’s life:
- Reduce dementia risk across the lifespan, by improving understanding of risk factors and putting evidence into practice where it may delay onset.
- Speed up discovery and innovation, including biomarkers, clinical trials and new prevention and treatment approaches.
- Improve dementia care from detection and diagnosis through treatment, coordination and moves between care settings.
- Strengthen services and supports for people living with dementia and their families, including caregiver support, home and community-based services, respite care and planning.
The plan also adds “related dementias” to its formal title, which HHS said reflects public comments and the shared problems families face across different forms of the disease. HHS said it will measure progress against each goal and report results in a 2027 update.
Kennedy tied the prevention push to his broader chronic disease agenda. “High blood pressure, diabetes, obesity and physical inactivity connect our work on dementia to a broader fight against all these other chronic diseases,” he said, as reported by WLRN.
What is the FDA’s Alzheimer’s Prevention Accelerator?
The FDA used the same event to launch a new program called the Neuroscience Advancement and Innovation Nexus, or NAIN. It pulls together experts from the agency’s drug, biologics and device centers to work on products for brain and nervous system conditions, from Alzheimer’s to psychiatric disorders, addiction and pain.
NAIN’s first project is the Alzheimer’s Prevention Accelerator. The FDA said it will look at new ways to run prevention and early-intervention trials, including who gets enrolled, which endpoints fit each stage of the disease, and what evidence can show that a product delays cognitive decline.
That last question has been a barrier for drugmakers, because Alzheimer’s changes in the brain begin years before symptoms. “New treatments have demonstrated that we can slow disease progression in patients with early symptoms, but we also know that slowing decline after symptoms appear is no longer enough,” Diamantas said, according to WLRN. He also noted that the FDA has now authorized four blood-based tests that can detect Alzheimer’s pathology.
What other federal money and programs are included?
HHS said agencies across the department are carrying out new and ongoing projects under the plan. The Advanced Research Projects Agency for Health announced up to $48.8 million for new Alzheimer’s projects focused on earlier detection and intervention, bringing its Alzheimer’s-related portfolio to as much as $155.3 million. The new work includes a biomarker-guided prevention trial platform at Mass General Brigham and an open-data research platform at Washington University in St. Louis.
Other pieces are smaller but closer to patients. The Administration for Community Living will expand brain health resources and training for elder justice professionals. HHS also plans more dementia training and screening at community health centers, crisis response resources for older adults with cognitive decline, a study of diagnostic delays and the economic burden of dementia, and a test of a lifestyle program for Medicare beneficiaries with mild cognitive impairment.
Why does the cost of dementia care matter so much?
Oz framed the issue in budget terms. “The last five years of an Alzheimer’s patient’s life is going to cost the government nearly $375,000. That is about 65% higher than what we spend for people who have heart disease, or people who have cancer,” he said at the event. He added that dementia cases are expected to more than double to 14 million people by 2060.
The Alzheimer’s Association estimates that 7.4 million Americans are living with dementia. Florida, where the announcement took place, is one of the hardest-hit states. Scott said nearly 600,000 Floridians live with Alzheimer’s, including more than 41,000 in Broward County alone, and he pointed to bills aimed at helping unpaid family caregivers.
What does this mean for families and caregivers?
In the short term, not much changes at the doctor’s office. The plan sets priorities and coordinates agencies. It doesn’t create a new benefit or guarantee new funding beyond the programs announced.
The bigger shift is in direction. A plan centered on risk reduction puts more weight on blood pressure, diabetes, exercise and early screening, and on keeping people with dementia safely at home longer. Families planning for that should look at home safety early, from fall prevention to the right home medical equipment and mobility aids. HNC’s guide to aging in place covers where to start.
The real test is whether the new trial approaches at the FDA lead to drugs that can be given to people before memory loss begins.
Key takeaways
- HHS released the 2026 update to the National Plan to Address Alzheimer’s Disease and Related Dementias on Oct. 22, 2026, in Fort Lauderdale, Florida.
- The plan replaces six goals with four, putting prevention and risk reduction first, and adds “related dementias” to its title.
- The FDA launched NAIN and its first project, the Alzheimer’s Prevention Accelerator, to rethink how prevention trials are designed and judged.
- ARPA-H announced up to $48.8 million for new Alzheimer’s projects. CMS says the last five years of an Alzheimer’s patient’s life cost nearly $375,000.
Frequently asked questions
What is the National Plan to Address Alzheimer’s Disease?
It is the federal government’s strategy for Alzheimer’s and related dementias, required under the National Alzheimer’s Project Act of 2011. HHS updates it regularly; the 2026 update was announced on Oct. 22, 2026.
What are the four goals of the 2026 Alzheimer’s plan?
Reduce dementia risk across the lifespan, speed up discovery and innovation, improve dementia care across the care journey, and strengthen services and supports for people living with dementia and their families.
What is the FDA Alzheimer’s Prevention Accelerator?
It is the first project of the FDA’s new Neuroscience Advancement and Innovation Nexus. It will explore new ways to design and evaluate clinical trials for drugs that could prevent or delay cognitive decline from Alzheimer’s disease.
Does the new plan give families new Medicare benefits?
No. The plan sets federal priorities and coordinates agencies. HHS said it will test a lifestyle intervention for Medicare beneficiaries with mild cognitive impairment, but it did not announce a new benefit.
